Pyridam Farma Tbk (JK:PYFA) — Market Cap & Net Worth
Market Cap & Net Worth: Pyridam Farma Tbk (PYFA)
Pyridam Farma Tbk (JK:PYFA) has a market capitalization of $198.84 Million (Rp3.39 Trillion) as of May 2, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #16552 globally and #244 in its home market, demonstrating a -19.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pyridam Farma Tbk's stock price Rp302.00 by its total outstanding shares 11236692042 (11.24 Billion). Analyse Pyridam Farma Tbk cash flow conversion to see how efficiently the company converts income to cash.
Pyridam Farma Tbk Market Cap History: 2015 to 2026
Pyridam Farma Tbk's market capitalization history from 2015 to 2026. Data shows growth from $71.19 Million to $198.84 Million (10.33% CAGR).
Index Memberships
Pyridam Farma Tbk is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Jakarta Stock Exchange Composite Index
JKSE
|
$540.85 Billion | 0.04% | #239 of 864 |
Weight: Pyridam Farma Tbk's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pyridam Farma Tbk Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pyridam Farma Tbk's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Pyridam Farma Tbk's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $71.19 Million | $217.84 Billion | $3.09 Billion | 0.00x | 0.02x |
| 2016 | $127.13 Million | $216.95 Billion | $5.15 Billion | 0.00x | 0.02x |
| 2017 | $117.96 Million | $223.00 Billion | $7.13 Billion | 0.00x | 0.02x |
| 2018 | $121.82 Million | $250.45 Billion | $8.45 Billion | 0.00x | 0.01x |
| 2019 | $130.37 Million | $247.11 Billion | $9.34 Billion | 0.00x | 0.01x |
| 2020 | $641.96 Million | $277.40 Billion | $22.10 Billion | 0.00x | 0.03x |
| 2021 | $668.30 Million | $630.53 Billion | $5.48 Billion | 0.00x | 0.12x |
| 2022 | $569.54 Million | $715.43 Billion | $275.24 Billion | 0.00x | 0.00x |
| 2023 | $753.90 Million | $702.07 Billion | -$85.22 Billion | 0.00x | N/A |
| 2024 | $138.27 Million | $1.92 Trillion | -$330.25 Billion | 0.00x | N/A |
Competitor Companies of PYFA by Market Capitalization
Companies near Pyridam Farma Tbk in the global market cap rankings as of May 2, 2026.
Key companies related to Pyridam Farma Tbk by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Pyridam Farma Tbk Historical Marketcap From 2015 to 2026
Between 2015 and today, Pyridam Farma Tbk's market cap moved from $71.19 Million to $ 198.84 Million, with a yearly change of 10.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp198.84 Million | -36.55% |
| 2025 | Rp313.41 Million | +126.67% |
| 2024 | Rp138.27 Million | -81.66% |
| 2023 | Rp753.90 Million | +32.37% |
| 2022 | Rp569.54 Million | -14.78% |
| 2021 | Rp668.30 Million | +4.10% |
| 2020 | Rp641.96 Million | +392.42% |
| 2019 | Rp130.37 Million | +7.01% |
| 2018 | Rp121.82 Million | +3.28% |
| 2017 | Rp117.96 Million | -7.22% |
| 2016 | Rp127.13 Million | +78.57% |
| 2015 | Rp71.19 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Pyridam Farma Tbk was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $198.84 Million USD |
| MoneyControl | $198.84 Million USD |
| MarketWatch | $198.84 Million USD |
| marketcap.company | $198.84 Million USD |
| Reuters | $198.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pyridam Farma Tbk
PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates through Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extra… Read more